X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (99) 99
female (64) 64
index medicus (62) 62
male (61) 61
middle aged (50) 50
adult (47) 47
aged (40) 40
hematology (40) 40
adolescent (35) 35
aged, 80 and over (24) 24
oncology (24) 24
germany (22) 22
medicine & public health (22) 22
pharmacology & pharmacy (22) 22
young adult (21) 21
risk factors (20) 20
survival (20) 20
chronic myeloid leukemia (19) 19
analysis (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (18) 18
treatment outcome (18) 18
leukemia, myelogenous, chronic, bcr-abl positive - mortality (17) 17
prognosis (17) 17
chronic myelogenous leukemia (15) 15
leukemia (15) 15
therapy (15) 15
clinical trials (14) 14
imatinib mesylate (12) 12
internal medicine (12) 12
prevalence (12) 12
public, environmental & occupational health (12) 12
risk (12) 12
survival analysis (12) 12
age (11) 11
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
interferon-alpha (11) 11
abridged index medicus (10) 10
cml (10) 10
cohort studies (10) 10
medical and health sciences (10) 10
medicin och hälsovetenskap (10) 10
public health (10) 10
age factors (9) 9
child (9) 9
chronic-phase (9) 9
disease-free survival (9) 9
drug therapy (9) 9
imatinib (9) 9
impact (9) 9
incidence (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - therapy (9) 9
piperazines - administration & dosage (9) 9
population (9) 9
prospective studies (9) 9
pyrimidines - administration & dosage (9) 9
remission induction (9) 9
risk assessment (9) 9
antineoplastic agents - therapeutic use (8) 8
asthma (8) 8
chronic myeloid-leukemia (8) 8
dose-response relationship, drug (8) 8
drug-related side effects and adverse reactions (8) 8
europe (8) 8
follow-up studies (8) 8
germany - epidemiology (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (8) 8
leukemia, myelogenous, chronic, bcr-abl positive - genetics (8) 8
medicine, general & internal (8) 8
pregnancy (8) 8
survival rate (8) 8
adverse drug reaction (7) 7
care and treatment (7) 7
clinical medicine (7) 7
diagnosis (7) 7
drugs (7) 7
epidemiology (7) 7
health aspects (7) 7
kaplan-meier estimate (7) 7
medical research (7) 7
prescription (7) 7
protein kinase inhibitors - administration & dosage (7) 7
recommendations (7) 7
time factors (7) 7
child, preschool (6) 6
chronic myeloid leukaemia (6) 6
comorbidity (6) 6
databases, factual (6) 6
disease progression (6) 6
hydroxyurea (6) 6
institut für medizinische informationsverarbeitung, biometrie und epidemiologie (6) 6
klinisk medicin (6) 6
medicine (6) 6
pediatrics (6) 6
pharmacoepidemiology (6) 6
pharmacology/toxicology (6) 6
pharmacovigilance (6) 6
retrospective studies (6) 6
severity of illness index (6) 6
tyrosine kinase inhibitors (6) 6
antihypertensive agents - therapeutic use (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, ISSN 1436-9990, 8/2017, Volume 60, Issue 8, pp. 830 - 835
Die EU-Verordnung 536/2014 (Clinical Trial Regulation, CTR) zur Neuregelung der klinischen Prüfung in der Europäischen Union und die dadurch erforderliche... 
Ethikkommission | EU Regulation 536/2014 | Public Health | Medicine & Public Health | Drug research | General Practice / Family Medicine | Klinische Prüfung | Clinical trials | EU-Verordnung Nr. 536/2014 | Arzneimittelforschung | Ethics committee
Journal Article
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, ISSN 1436-9990, 08/2017, Volume 60, Issue 8, p. 830
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00103-017-2580-3 Die... 
Medical research | Ethics | Laws, regulations and rules | Medicine, Experimental | Medical ethics
Journal Article
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, ISSN 1436-9990, 06/2019, Volume 62, Issue 6, p. 682
In Deutschland sind Ethikkommissionen zustandig fur die Beurteilung aller Bereiche biomedizinischer Forschung am Menschen. Sie wurden nach Landesrecht bei den... 
Medical equipment | Medical research | Medical societies | Medicine, Experimental | Research ethics | Physiological apparatus | Drug approval | Ethical aspects | Medical ethics
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 12, pp. 1634 - 1642
Journal Article
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, ISSN 1436-9990, 6/2019, Volume 62, Issue 6, pp. 682 - 689
In Deutschland sind Ethikkommissionen zuständig für die Beurteilung aller Bereiche biomedizinischer Forschung am Menschen. Sie wurden nach Landesrecht bei den... 
Verfahren | Public Health | Biomedical research | Criteria for evaluation | General Practice / Family Medicine | Beurteilungskriterien | Protection of participants | Functioning | Öffentlich-rechtliche Ethikkommissionen | Medicine & Public Health | Medizinische Forschung | Research ethics committees | Probanden‑/Patientenschutz
Journal Article
Journal Article
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, ISSN 1436-9990, 08/2017, Volume 60, Issue 8, p. 893
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00103-017-2588-8 
Clinical trials
Journal Article
Journal Article
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, ISSN 1436-9990, 05/2017, Volume 60, Issue 5, p. 556
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00103-017-2537-6 Seltene... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2005, Volume 23, Issue 9, pp. 1984 - 1992
Journal Article
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 06/2019, Volume 62, Issue 6, p. 682
In Germany, the only research ethics committees (RECs) that are entitled to assess all fields of biomedical research are those set up according to state law by... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2012, Volume 30, Issue 29, pp. 3604 - 3610
Journal Article